Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646157 | 0.76 | PARP1 (0.50) | PARP1MEN1KMT2A | |
| SCHEMBL25919036 | 0.76 | PARP1 (0.42) | PARP1KCNH2PARP2MEN1KMT2A | |
| SCHEMBL6069754 | 0.76 | MAPT (0.51) | PARP1KCNH2PARP2CCNB2CDK1 | |
| SCHEMBL6643842 | 0.76 | KDM4E (0.51) | PARP1KCNH2PARP2HSD17B10GRIN2D | |
| SCHEMBL6070704 | 0.75 | TTR (0.46) | PARP1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL6137514 | 0.75 | TTR (0.46) | PARP1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL25153943 | 0.73 | KDM4E (0.48) | PARP1KCNH2PARP2HSD17B10GRIN2D | |
| SCHEMBL6408399 | 0.73 | PARP1 (0.57) | PARP1KCNH2PARP2 | |
| SCHEMBL6407884 | 0.73 | HSD17B10 (0.51) | PARP1KCNH2PARP2CCNB2CDK1 | |
| SCHEMBL25093574 | 0.73 | PARP1 (0.52) | PARP1KCNH2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067667-B2 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-27 | — | — | US | disclosed |
| EP-1129077-B9 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1129077-B1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AG (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | JAROCH STEFAN (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1115708-B1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | SCHERING AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-6579883-B1 | Nitrogen monoxide synthases; 4-amino-8-bromo-3a-fluoro-2,3,3a,9b-tetrahydro-1H-cyclopenta (c) quinoline; neurodegenerative, autoimmune, cardiovascular diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-17 | — | — | US | disclosed |
| EP-1129077-A1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1115708-A1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000029381-A1 | FLUORINATED 3,4-DIHYDROQUINOLINE DERIVATIVES USED AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000017167-A1 | AMINOALKYL-3,4-DIHYDROQUINOLINE DERIVATES AS NO-SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | NOS3, NOS1, NOS2 | PARP1 1058/4885KCNH2 1867/4885PARP2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.